Valuation: Alkermes plc

Market Cap 7.76B 6.96B 6.41B 5.82B 11.02B 727B 11.33B 76.78B 30.59B 390B 29.12B 28.5B 1,232B P/E 2026 *
-96.8x
P/E 2027 * 104x
Enterprise Value 8.82B 7.91B 7.29B 6.62B 12.52B 827B 12.87B 87.25B 34.76B 443B 33.09B 32.39B 1,400B EV / Sales 2026 *
4.83x
EV / Sales 2027 * 4.47x
Free-Float
89.46%
Yield 2026 *
-
Yield 2027 * -
1 day+0.65%
1 week+3.52%
Current month+2.49%
1 month+14.43%
3 months-5.49%
6 months+32.81%
Current year+66.08%
1 week 44.07
Extreme 44.07
47.07
1 month 38.98
Extreme 38.98
47.43
Current year 27
Extreme 27
55.67
1 year 27
Extreme 27
55.67
3 years 22.06
Extreme 22.06
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 53 01/08/2026
Director/Board Member 74 26/05/2016
Date Insider Type Main position Quantity % Market Cap. Importance
11/3/26 A Sell

Compliance Officer

-2,035 0.0012%
10/8/26 A Exercice

Chief Financial Officer

22,397 0.0134%
10/7/26 A Free

Director

25,237 0.0150%
Change 5-day change 1-year change 3-year change Capi.($)
+0.65%+3.52%+41.29%+89.60% 7.76B
+1.44%+1.51%+54.95%+142.22% 1,258B
-0.47%+3.78%+50.50%+90.46% 679B
+0.20%+1.75%+34.10%+112.90% 518B
+0.17%+1.16%+49.70%+68.75% 390B
-0.48%-0.21%+71.59%+44.61% 367B
+0.76%+2.25%+31.84%+59.53% 307B
-1.29%+0.17%+7.63%+33.04% 293B
0.00%-0.05%+45.29%+76.18% 252B
+0.92%+0.32%+43.78%+127.89% 210B
Average +0.09%+1.23%+43.07%+84.52% 428B
Weighted average by Cap. +0.02%+1.18%+46.63%+97.33%

Financials

2026 *2027 *
Net sales 1.82B 1.64B 1.51B 1.37B 2.59B 171B 2.66B 18.05B 7.19B 91.63B 6.85B 6.7B 290B 1.92B 1.73B 1.59B 1.44B 2.73B 180B 2.81B 19.04B 7.59B 96.66B 7.22B 7.07B 306B
Net income -84.46M -75.74M -69.81M -63.4M -120M -7.92B -123M -836M -333M -4.24B -317M -310M -13.41B 79.36M 71.17M 65.59M 59.57M 113M 7.44B 116M 785M 313M 3.99B 298M 292M 12.6B
Net Debt 1.06B 949M 875M 794M 1.5B 99.23B 1.55B 10.47B 4.17B 53.17B 3.97B 3.89B 168B 840M 754M 695M 631M 1.19B 78.79B 1.23B 8.32B 3.31B 42.21B 3.15B 3.09B 133B
Projected Income Statement - Annual - Alkermes plc
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
10/11/26 $46.47 +0.65% 1,035,989
09/11/26 $46.17 +0.59% 1,709,146
06/11/26 $45.90 +3.05% 1,673,442
05/11/26 $44.54 -2.94% 1,943,983
04/11/26 $45.89 +0.44% 2,179,091
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Alkermes plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
46.17USD
Average target price
57.74USD
Spread / Average Target
+25.05%
  1. Stock Market
  2. Stocks
  3. ALKS Stock